AGM / EGM Postponed to July 20, 2008

Name	Symbol	Market	Type
XTL Biopharmaceuticals Ltd	NASDAQ:XTLB	NASDAQ	Depository Receipt

Name

Symbol

Market

Type

XTL Biopharmaceuticals Ltd

NASDAQ:XTLB

NASDAQ

Depository Receipt

	Price Change	% Change	Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.2733	10.16%	2.9633	2.66	3.49	3.04	2.71	2.71	77,510	22:55:48

Price Change

% Change

Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Traded

Last Trade

0.2733

10.16%

2.9633

2.66

3.49

3.04

2.71

77,510

22:55:48

AGM / EGM Postponed to July 20, 2008

17/07/2008 4:10pm

PR Newswire (US)

XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart

From Jul 2019 to Jul 2024

Click Here for more XTL Biopharmaceuticals Charts.

VALLEY COTTAGE, N.Y., July 17 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces that the Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") scheduled for today were adjourned and postponed until Sunday, July 20, 2008 at 4:00pm and 4:30 pm Israel time, respectively. ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT: Ron Bentsur, Chief Executive Officer, XTL Biopharmaceuticals Ltd., +1-845-267-0707 ext. 225

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

XTLB XTL Biopharmaceuticals Ltd